Marker Therapeutics Files 8-K
Ticker: MRKR · Form: 8-K · Filed: May 20, 2025 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | 8-K |
| Filed Date | May 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, corporate-actions
Related Tickers: MRKR
TL;DR
Marker Therapeutics (MRKR) filed an 8-K on 5/20/25. No major news, just standard filings.
AI Summary
Marker Therapeutics, Inc. filed an 8-K on May 20, 2025, reporting other events and financial statements. The company, formerly known as TAPIMMUNE INC. and GENEMAX CORP, is incorporated in Delaware and headquartered in Houston, Texas.
Why It Matters
This filing provides an update on significant events and financial disclosures for Marker Therapeutics, Inc., which could impact investor understanding of the company's current status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting other events and financial statements, with no immediate indication of significant new risks.
Key Numbers
- 001-37939 — SEC File Number (Identifier for Marker Therapeutics' SEC filings)
- 20250520 — Report Date (Date of the earliest event reported in the 8-K)
Key Players & Entities
- Marker Therapeutics, Inc. (company) — Registrant
- TAPIMMUNE INC. (company) — Former company name
- GENEMAX CORP (company) — Former company name
- 2450 Holcombe Blvd (location) — Principal executive address
- Houston, Texas (location) — Principal executive address
FAQ
What specific 'Other Events' are detailed in this 8-K filing?
The provided text does not specify the 'Other Events' beyond listing it as an item information category.
When was Marker Therapeutics, Inc. previously known as TAPIMMUNE INC. or GENEMAX CORP?
The filing indicates name changes from GENEMAX CORP to TAPIMMUNE INC. in 20020718 and from TAPIMMUNE INC. to Marker Therapeutics, Inc. in 20170629.
What is the primary business of Marker Therapeutics, Inc. based on its SIC code?
Marker Therapeutics, Inc. is classified under SIC code 2834, which corresponds to Pharmaceutical Preparations.
Where is Marker Therapeutics, Inc. headquartered?
The company's principal executive address is located at 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, Texas 77021.
What is the fiscal year end for Marker Therapeutics, Inc.?
The fiscal year end for Marker Therapeutics, Inc. is December 31 (1231).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 20, 2025 regarding Marker Therapeutics, Inc. (MRKR).